Pfizer’s RSV vaccine granted FDA Breakthrough Therapy Status
Pfizer has secured the Breakthrough designation for its RSV vaccine RSVpreF this week. The US FDA has granted RSVpreF this coveted status base on a phase 2b proof of concept study. This also comes at a time when GSK, another player in this segment has faced a setback after the safety assessment of its vaccine….
News Views